Diabetes Drug Exendin-4 May Help Overcome Prostate Cancer Drug Resistance
The GLP-1 analog exendin-4 enhanced prostate cancer sensitivity to enzalutamide by suppressing the PI3K/Akt/mTOR resistance pathway in both cell and animal models.
Quick Facts
What This Study Found
Exendin-4 combined with enzalutamide significantly suppressed prostate cancer tumor growth compared to enzalutamide alone by inhibiting Akt and mTOR activation triggered by enzalutamide resistance.
Key Numbers
Exendin-4 plus enzalutamide produced significantly greater tumor shrinkage than either agent alone; Akt pathway suppressed.
How They Did This
In vitro experiments with LNCaP and CWR22RV1 prostate cancer cell lines plus in vivo xenograft mouse models. Measured tumor growth, invasion, migration, and key signaling pathway proteins.
Why This Research Matters
Drug resistance is a major problem in prostate cancer treatment. Repurposing an existing diabetes peptide drug to overcome resistance could provide a faster path to clinical use than developing entirely new compounds.
The Bigger Picture
GLP-1 receptor agonists are increasingly being studied for effects beyond diabetes, including potential anti-cancer properties. This study adds prostate cancer drug resistance to the list of conditions where these peptides may offer therapeutic benefit.
What This Study Doesn't Tell Us
Animal study using xenograft models, which don't fully replicate human prostate cancer biology. Clinical doses and safety of exendin-4 in cancer patients haven't been established. One noted P-value (P < .5) appears to be a typo and may be less significant than intended.
Questions This Raises
- ?Would this combination approach work in human clinical trials for castration-resistant prostate cancer?
- ?Do other GLP-1 analogs like semaglutide or liraglutide have similar anti-resistance effects?
- ?What is the optimal dosing of exendin-4 for anti-cancer effects versus its metabolic effects?
Trust & Context
- Key Stat:
- P < .05 significance level for combination therapy reducing cancer cell invasion vs. enzalutamide alone
- Evidence Grade:
- Pre-clinical evidence from cell lines and mouse xenografts. Promising but requires human clinical trials to confirm therapeutic relevance.
- Study Age:
- Published in 2020. Interest in GLP-1 agonists for cancer applications has grown significantly since.
- Original Title:
- Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
- Published In:
- The Prostate, 80(5), 367-375 (2020)
- Authors:
- Wenjing, He, Shao, Yuanyuan, Yu, Yi, Huang, Wei, Feng, Guoliang, Li, Junhe
- Database ID:
- RPEP-05197
Evidence Hierarchy
Frequently Asked Questions
What is enzalutamide resistance?
Enzalutamide blocks androgen receptor signaling in prostate cancer, but tumors can develop resistance by activating alternative survival pathways like PI3K/Akt/mTOR.
Is exendin-4 the same as drugs like Ozempic?
Exendin-4 is a GLP-1 receptor agonist in the same drug class as semaglutide (Ozempic/Wegovy), though it's a different molecule originally derived from Gila monster venom.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05197APA
Wenjing, He; Shao, Yuanyuan; Yu, Yi; Huang, Wei; Feng, Guoliang; Li, Junhe. (2020). Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.. The Prostate, 80(5), 367-375. https://doi.org/10.1002/pros.23951
MLA
Wenjing, He, et al. "Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.." The Prostate, 2020. https://doi.org/10.1002/pros.23951
RethinkPeptides
RethinkPeptides Research Database. "Exendin-4 enhances the sensitivity of prostate cancer to enz..." RPEP-05197. Retrieved from https://rethinkpeptides.com/research/wenjing-2020-exendin4-enhances-the-sensitivity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.